Multienzyme Complexes Or Mixtures Of Enzymes Patents (Class 424/94.2)
-
Patent number: 9492515Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.Type: GrantFiled: February 3, 2015Date of Patent: November 15, 2016Assignee: CUREMARK, LLCInventors: Joan M. Fallon, Matthew Heil, James Szigethy, James Fallon
-
Patent number: 9353300Abstract: Adhesives made from phosphorylated legume and oil seed flours are described. The adhesive composition includes water and a legume and/or oil seed flour in which at least a portion of ?-amino moieties in lysine residues present in the flour are phosphorylated. An oxidizing agent may also optionally be added to the adhesive composition.Type: GrantFiled: May 30, 2014Date of Patent: May 31, 2016Assignee: Wisconsin Alumni Research FoundationInventors: Srinivasan Damodaran, Dani Zhu
-
Patent number: 9320759Abstract: Methods and compositions for treating, reducing, or preventing deterioration of at least one component of the visual system of an animal are disclosed. The methods comprise administering to the animal a composition comprising UFA and NORC in an amount effective to treat, reduce, or prevent deterioration of at least one component of the visual system. Methods extending the prime years of an animal's life, improving the quality of life, and promoting health and wellness of an animal using compositions comprising UFA and NORC are also disclosed.Type: GrantFiled: January 24, 2012Date of Patent: April 26, 2016Assignee: Nestec S.AInventor: Yuanlong Pan
-
Patent number: 9267128Abstract: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.Type: GrantFiled: March 30, 2012Date of Patent: February 23, 2016Assignee: Alvine Pharmaceuticals, Inc.Inventor: Pawan Kumar
-
Patent number: 9216209Abstract: A process for the endogenic catabolism of homocysteine and the control of homocysteine levels for treating disease and the degenerative diseases of aging is provided along with pharmaceutical compositions having thioretinamide, retinol or combinations thereof in combination with an enzyme or a pro-enzyme. The process includes the catabolism of homocysteine thiolactone in cells and tissues by catalyzing the reaction of homocysteine thiolactone with an enzyme-bound retinoic acid to increase the bioavailability of thioretinamide in diseased and aged cells and tissue.Type: GrantFiled: June 6, 2011Date of Patent: December 22, 2015Inventor: Kilmer S. McCully
-
Patent number: 9169496Abstract: Described is a method for the enzymatic production of butadiene which allows to produce butadiene from crotyl alcohol. Also described are enzyme combinations and compositions containing such enzyme combinations which allow the enzymatic conversion of crotyl alcohol into butadiene. Furthermore, the invention relates to microorganisms which have been genetically modified so as to be able to produce butadiene from crotyl alcohol. Moreover, the invention relates to a method for the enzymatic production of crotyl alcohol from crotonyl-Coenzyme A. The obtained crotyl alcohol can be further converted into butadiene as described herein. Also described are enzyme combinations which allow to convert crotonyl-Coenzyme A into crotyl alcohol as well as (micro)organisms which express such enzyme combinations.Type: GrantFiled: October 18, 2012Date of Patent: October 27, 2015Assignee: Scientist of Fortune, S.A.Inventor: Philippe Marliere
-
Patent number: 9169329Abstract: The present invention relates to antibodies that specifically bind to unprocessed c-Met present on the surface of tumor cells. These antibodies are useful in the diagnosis and treatment of cancer or as agents for delivering moieties to cancer cells. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents.Type: GrantFiled: June 1, 2011Date of Patent: October 27, 2015Assignees: Ludwig Institute for Cancer Research, Monash UniversityInventors: Terrance Grant Johns, Ermanno Gherardi, Andrew Mark Scott
-
Patent number: 9149513Abstract: Methods for treating male sub-fertility by administering a pharmaceutical composition to a subject in need thereof are provided. The pharmaceutical compositions include an agent that causes a reduction in an effect of extracellular DNA on sperm cells. The agent may be, for example, an enzyme that degrades DNA such as DNase, a substance that blocks the interaction between cell free DNA and sperm cell surface receptors, a substance that binds to DNA, a substance that inhibits endogenous sperm cell DNase, a substance that inhibits a member of a signal transduction pathway mediated by DNA binding to sperm cell surface receptors, or an agent that stimulates production of an endogenous substance that causes a reduction in an antifertility effect of cell free DNA on sperm cells.Type: GrantFiled: December 20, 2012Date of Patent: October 6, 2015Assignee: PERINESS LTD.Inventors: Benjamin Bartoov, Ronen Yehuda, Melamed Dobroslav
-
Patent number: 9057081Abstract: The present invention relates to cell wall degradative systems, in particular to systems containing enzymes that bind to and/or depolymerize cellulose, hemicellulose and other carbohydrates. These systems have a number of applications.Type: GrantFiled: April 30, 2008Date of Patent: June 16, 2015Assignee: Aemetis Technologies, Inc.Inventors: Steven Hutcheson, Ronald Weiner
-
Patent number: 9040040Abstract: Tissue fixed charge density (FCD) is identified as another potential therapeutic target for reducing brain tissue swelling. Reduction of the FCD could reduce the thermodynamic force driving water entry into the brain. The present invention discloses chondroitinase ABC (ChABC) reduces tissue FCD and reduces tissue swelling, indicating that it may be an effective treatment to reduce edema and control intracranial pressure.Type: GrantFiled: May 23, 2013Date of Patent: May 26, 2015Assignee: The Trustees of Columbia University in the City of New YorkInventors: Benjamin Simon Elkin, Barclay Morrison, III, John Desmond Finan
-
Publication number: 20150132273Abstract: A nutritional supplement that contains folinic acid, folic acid, USP, methylfolic acid, cobalamin, magnesium, docosahexaenoic acid, phosphatidylcholine-docosahexaenoic acid, phosphatidylethanolamine-docosahexaenoic acid. A nutritional supplement is disclosed for the treatment of cognitive disorders, attention deficit disorder, oxidative stress, depression, memory loss, anxiety, and apathy.Type: ApplicationFiled: December 30, 2013Publication date: May 14, 2015Inventor: Rhett Sean Daniels
-
Patent number: 9029115Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.Type: GrantFiled: August 16, 2012Date of Patent: May 12, 2015Assignees: Novozymes A/S, Novozymes IncInventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
-
Publication number: 20150118189Abstract: The invention relates to the field of microbiology, specifically to a combination of a source of a first enzymatic active domain and a source of a second enzymatic active domain and to a composition comprising said combination. The invention further relates to a composition comprising said combination for use as a medicament, to the use of said composition as an antimicrobial agent and to a method for controlling microbial contamination in a food- or feed product, on and/or in food- or feed processing equipment, on and/or in food- or feed containers.Type: ApplicationFiled: May 7, 2013Publication date: April 30, 2015Applicant: MICREOS HUMAN HEALTH B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Publication number: 20150118211Abstract: The invention provides methods, compositions, and kits for removal of biofilms from surfaces. The methods described herein comprise simultaneous or sequential application of a perhydrolase enzyme and a mixture of other enzymes, such as proteases, glucanases, esterases, mannanases, phospholipases, cellulases, and/or amylases, to a biofilm on a surface, to effect removal of the biofilm.Type: ApplicationFiled: November 1, 2013Publication date: April 30, 2015Applicant: Danisco US Inc.Inventors: Christopher C. Barnett, Manoj Kumar, Gregory M. Whited
-
Publication number: 20150110765Abstract: The present invention relates to isolated polypeptides having alpha-glucuronidase activity, catalytic domains and polynucleotides encoding the polypeptides, catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides or catalytic domains.Type: ApplicationFiled: April 22, 2013Publication date: April 23, 2015Inventors: Johan Börjesson, Anders Vikø-Nielsen, Nikolaj Spodsberg, Kristian Krogh
-
Patent number: 9011842Abstract: The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also be used as a prophylactic to reduce exposure to gluten oligopeptides.Type: GrantFiled: February 2, 2011Date of Patent: April 21, 2015Assignees: Amano Enzyme Inc., Amano Enzyme USA Co., Ltd.Inventors: James F. Jolly, Horoki Ido, Hirotaka Matsubara, Tetsuya Takahashi, Kyoichi Nishio
-
Patent number: 9011964Abstract: A mixed dose of a nanosized drug wherein at least one portion of the mixed dose comprises a core nanosized drug encapsulated in at least one layer of a protective material having the same core drug or different core drug. A mixed dose of a nanosized drug wherein at least one portion of the mixed dose comprises a core nanosized drug encapsulated in at least one shell of a protective material with same drug concentration or different drug concentrations. A mixed dose of a nanosized drug wherein at least one portion of the mixed dose comprises a core nanosized drug encapsulated such that it has different release schedule than other portions of the drug. Methods and systems for manufacturing and administration of nanosized encapsulated drugs are also provided.Type: GrantFiled: December 6, 2014Date of Patent: April 21, 2015Inventor: Albert S. Zeng
-
Publication number: 20150104489Abstract: The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilising a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilising product impregnated with or containing at least deoxyribonuclease.Type: ApplicationFiled: May 8, 2013Publication date: April 16, 2015Applicant: London School of Hygiene and Tropical MedicineInventors: Lisa Dawson, Brendan Wren
-
Publication number: 20150098932Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.Type: ApplicationFiled: December 16, 2014Publication date: April 9, 2015Inventor: Sarah Bacus
-
Publication number: 20150093369Abstract: The invention concerns a mixture of enzymes from krill for use in the treatment of a soft tissue including epithelial tissue and mucosa on which soft tissue a biofilm has formed or is expected to form, which soft tissue is a soft tissue of a mammal and which treatment comprises the removal of the biofilm or preventing a formation of the biofilm.Type: ApplicationFiled: March 15, 2013Publication date: April 2, 2015Applicant: ARCIMBOLDO ABInventors: Max Rutman, Wolfgang Vanscheidt, Jan Vincent, Frank Kochinke
-
Publication number: 20150079061Abstract: The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins. In one embodiment, the method includes lyophilizing the blast frozen component to remove at least some water from the blast frozen component thereby creating a freeze-dried form; and storing the lyophilized component; wherein the lyophilized component includes the proteins. The invention also provides a composition including proteins from at least one lyophilized, blast frozen component of a harvested mammalian feto-placental unit reconstituted with a fluid.Type: ApplicationFiled: July 14, 2014Publication date: March 19, 2015Inventors: Patrick J. Casey, Murray Hoare
-
Publication number: 20150079062Abstract: The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins. In one embodiment, the method includes lyophilizing the blast frozen component to remove at least some water from the blast frozen component thereby creating a freeze-dried form; and storing the lyophilized component; wherein the lyophilized component includes the proteins. The invention also provides a composition including proteins from at least one lyophilized, blast frozen component of a harvested mammalian feto-placental unit reconstituted with a fluid.Type: ApplicationFiled: November 24, 2014Publication date: March 19, 2015Inventors: Patrick J. Casey, Murray Hoare
-
Patent number: 8980252Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.Type: GrantFiled: April 20, 2012Date of Patent: March 17, 2015Assignee: Curemark LLCInventors: Joan Fallon, Matthew Heil, James Szigethy, James Fallon
-
Publication number: 20150064156Abstract: The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.Type: ApplicationFiled: September 9, 2014Publication date: March 5, 2015Inventors: Vincent A. Fischetti, Anu Daniel, Chad Euler
-
Patent number: 8940295Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.Type: GrantFiled: March 27, 2013Date of Patent: January 27, 2015Assignee: Oxthera Intellectual Property ABInventors: Harmeet Sidhu, Aaron Blake Cowley, Carl-Gustaf Golander, Qingshan Li
-
Publication number: 20150023944Abstract: A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.Type: ApplicationFiled: September 23, 2014Publication date: January 22, 2015Inventor: Joan M. Fallon
-
Publication number: 20150017186Abstract: Provided are compositions and combinations containing an organophosphorus bioscavenger and a hyaluronan-degrading enzyme. The provided compositions and combinations can be used to treat or prevent organophosphorus poisoning, including nerve agent poisoning and pesticide poisoning.Type: ApplicationFiled: September 8, 2014Publication date: January 15, 2015Inventors: John K. Troyer, Elizabeth Leffel
-
Publication number: 20140363478Abstract: There is provided an anti-fouling composition comprising (i) a surface coating material; (ii) an enzyme obtained or obtainable from a marine organism; and (iii)(a) a substrate for the enzyme; and/or (b) a precursor enzyme and a precursor substrate, wherein the precursor enzyme and the precursor substrate are selected such that a substrate for the enzyme is generatable by action of the precursor enzyme on the precursor substrate; wherein the enzyme and the substrate are selected such that an anti-foulant compound is generatable by action of the enzyme on the substrate.Type: ApplicationFiled: March 21, 2014Publication date: December 11, 2014Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: Charlotte Horsmans Poulsen, Karsten Matthias Kragh
-
Publication number: 20140348881Abstract: A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.Type: ApplicationFiled: June 4, 2014Publication date: November 27, 2014Inventor: Joan M. Fallon
-
Patent number: 8895282Abstract: A method for treatment and/or prevention of common cold caused by rhinovirus, wherein a patient in need is treated with a medicament including a hydrogen peroxide producing enzyme.Type: GrantFiled: March 20, 2009Date of Patent: November 25, 2014Assignee: Tanomed ABInventor: Krister Tano
-
Patent number: 8889119Abstract: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and ?-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and ?-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.Type: GrantFiled: September 7, 2013Date of Patent: November 18, 2014Assignee: Master Supplements, Inc.Inventors: Randolph S. Porubcan, Sonja L. Yonak
-
Publication number: 20140328818Abstract: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.Type: ApplicationFiled: March 30, 2012Publication date: November 6, 2014Applicant: ALVINE PHARMACEUTICALS, INC.Inventor: Pawan Kumar
-
Publication number: 20140322190Abstract: Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator.Type: ApplicationFiled: July 9, 2014Publication date: October 30, 2014Applicant: Northwestern UniversityInventors: Melina R. Kibbe, Guillermo A. Ameer, Vinit N. Varu
-
Publication number: 20140314732Abstract: Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG).Type: ApplicationFiled: February 25, 2014Publication date: October 23, 2014Applicant: Lifebond Ltd.Inventor: Orahn PREISS-BLOOM
-
Patent number: 8865160Abstract: The present invention is directed to compositions and methods of preserving viability of islets of Langerhans for transplantation, and treating various diseases and other abnormal or pathological conditions, including inflammatory bowel disease, ischemic heart disease, acute lung injury, acute respiratory distress syndrome and radiation-induced brain injury, with DNA repair enzymes that are directed to the mitochondria.Type: GrantFiled: February 9, 2009Date of Patent: October 21, 2014Assignee: University of South AlabamaInventors: Glenn Wilson, Susan Ledoux, Mikhail Alexeyev, Inna Shokolenko, Mark N. Gillespie
-
Publication number: 20140302000Abstract: Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans.Type: ApplicationFiled: June 18, 2014Publication date: October 9, 2014Inventors: George Shlieout, Bernd Boedecker, Siegfried Schaefer, Bernd Thumbeck, Peter-Colin Gregory
-
Patent number: 8846064Abstract: A cosmetic and pharmaceutical formulation for rejuvenation and restoration of the skin, and methods of making this formulation. The cosmetic and pharmaceutical formulations comprise liposomes containing partially acylated proteins with a modification level of 0.1 to 10% of their mass, wherein the proteins are present in the form of a supramolecular assembly.Type: GrantFiled: February 1, 2011Date of Patent: September 30, 2014Inventors: Artur Martynov, Boris S. Farber, Sonya Sophya Farber, Aleksandr Sitenko
-
Patent number: 8846033Abstract: The invention relates to a dietary supplement that promotes proper ingestion and proper digestion of animal and/or vegetable proteins. The supplement comprises an enzyme mixture containing amylase, lactase and bromelain in the following dosage by weight: 15 mg to 90 mg amylase, 18 mg to 90 mg lactase and 6 mg to 80 mg bromelain.Type: GrantFiled: June 16, 2008Date of Patent: September 30, 2014Assignee: ET & DS Company Ltd.Inventor: Christian Chossade
-
Publication number: 20140286924Abstract: An agent for use in the case of disorders of blood sugar metabolism, including diabetes, is described, which reduces the glucose content of food and other substances with the help of 5-D-fructose dehydrogenase and glucose isomerase.Type: ApplicationFiled: December 26, 2013Publication date: September 25, 2014Applicant: PRO NATURA GESELLSCHAFT FUER GESUNDE ERNAEHRUNG MBInventors: Daniel Henry WYROBNIK, Isaac Harry WYROBNIK
-
Publication number: 20140276632Abstract: The present invention provides a process for the preparation of a stable and homogeneous liquid composition that is suitable for enteral administration comprising a digestive enzyme product and nutrients from a nutritional formula having specific amount of nutrients. The invention further provides a method for efficiently and effectively administering a therapeutically effective dose of the stable and homogeneous liquid composition by means of an enteral tube.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Aptalis Pharma Ltd.Inventors: Vincenza PIRONTI, Emanuela RONDA, Luigi BOLTRI
-
Publication number: 20140271597Abstract: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met.Type: ApplicationFiled: March 24, 2014Publication date: September 18, 2014Applicant: Osio Corporation d/b/a Yolia HealthInventor: Alberto Osio Sancho
-
Publication number: 20140248251Abstract: The invention concerns methods for protecting a subject in need from a deleterious effect of gluten ingestion. The invention specifically concerns the treatment of celiac disease and gluten intolerance. The invention further provides pharmaceutical compositions for protecting a subject in need from a deleterious effect of gluten ingestion, and, in particular, for treating celiac disease and gluten intolerance. Oral administration of ALV003 can protect celiac disease patients and patients otherwise suffering from gluten-intolerance from the harmful effects of ingesting food containing gluten.Type: ApplicationFiled: July 25, 2012Publication date: September 4, 2014Inventor: Daniel C. Adelman
-
Publication number: 20140248250Abstract: The drug has a bactericidal effect on vegetative and spore cells of Bacillus anthracis and comprises a bacteriolytic complex produced by Lysobacter sp. XL 1. The bacteriolytic complex produced by is in a method of anthrax prevention and treatment.Type: ApplicationFiled: December 6, 2011Publication date: September 4, 2014Inventors: Nina Andreevna Schischkova, Nikolai Andreevich Starizin, Leonid Ivanovich Marinin, Olga Andreevna Stepnava, Igor Stepanovich Kulaev, Irina Matveevna Zfasman, elena Albertovna Begunova, Irina Alexandrovna Chaika
-
Publication number: 20140242036Abstract: The instant invention refers to a novel process for potentiating the production of substances with antifungal activity obtained from Ganoderma lucidum, using a technological device for the differential, qualitative and quantitative expression of proteins and other bioactive molecules, selected from the group consisting of polysaccharides, triterpenoids, fatty acids and ganoderic acids. The compositions containing said substances showed antifungal activity and mycelium growth and fungi ascospore germination inhibiting activity, amongst them Mycosphaerella fijiensis, primary pathogenic agent causing black Sigatoka disease in banana and plantain crop fields.Type: ApplicationFiled: June 18, 2013Publication date: August 28, 2014Inventors: JOHN JAIRO MIRA CASTILLO, PAOLA ANDREA ZAPATA OCAMPO, LUCíA ATEHORTÚA GARCÉS, LIUDA JOHANA SEPÚLVEDA ARANGO, DIEGO FERNANDO ROJAS VAHOS
-
Patent number: 8815233Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.Type: GrantFiled: April 16, 2012Date of Patent: August 26, 2014Assignee: Curemark LLCInventor: Joan M. Fallon
-
Publication number: 20140234279Abstract: A feed additive composition comprising a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject, which method comprising administering to a subject a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase.Type: ApplicationFiled: January 19, 2012Publication date: August 21, 2014Applicant: DUPONT NUTRITION BIOSCIENCES APSInventor: Luis Fernando Romero Millan
-
Patent number: 8802087Abstract: Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans.Type: GrantFiled: March 22, 2005Date of Patent: August 12, 2014Assignee: Abbott Products GmbHInventors: George Shlieout, Bernd Boedecker, Siegfried Schaefer, Bernd Thumbeck, Peter-Colin Gregory
-
Patent number: 8802729Abstract: Biodegradable detergent compositions comprising enzymes and 1,3-propanediol are provided. The 1,3-propanediol in the composition is biologically derived and enhances the stability of the enzymes in the composition. The compositions also exhibit a low anthropogenic CO2 emission profile.Type: GrantFiled: March 15, 2013Date of Patent: August 12, 2014Assignee: DuPont Tate & Lyle Bio Products Company, LLCInventors: Gyorgyi Fenyvesi, Melissa Joerger, Robert Miller, Raja Hari Poladi, Ann Wehner
-
Publication number: 20140219982Abstract: The present invention is intended to provide a means for efficiently degrades exogenous opioid peptides. Provided is an exogenous opioid peptide-degrading enzyme preparation which contains one or more components selected from the group consisting of enzyme preparations from Penicillium citrinum, Aspergillus oryzae, and Aspergilius melleus, and exhibits a degradation activity for a wheat gluten-derived opioid peptide and a casein-derived opioid peptide.Type: ApplicationFiled: August 31, 2012Publication date: August 7, 2014Applicant: AMANO ENZYME INC.Inventors: Hirotaka Matsubara, Hiroki Ido, Satoshi Koikeda
-
Publication number: 20140212492Abstract: The present disclosure describes compositions for intestinal delivery of enzyme formulations and methods of treating health problems with these formulations. More specifically, the enzyme formulations include at least one histaminase and various methods of treatment of physical conditions, such as inflammation, allergy, histamine intolerance, and intestinal cancer.Type: ApplicationFiled: April 5, 2012Publication date: July 31, 2014Applicant: HISTAPHARM INC.Inventors: Mircea-Alexandru Mateescu, Carmen Calinescu, Pompilia Ispas-Szabo, Bruno Mondovi, Rodolfo Federico